Natera, Inc. (NTRA): Price and Financial Metrics
NTRA Price/Volume Stats
| Current price | $91.11 | 52-week high | $98.82 |
| Prev. close | $90.42 | 52-week low | $36.90 |
| Day low | $89.72 | Volume | 776,500 |
| Day high | $91.50 | Avg. volume | 1,471,796 |
| 50-day MA | $84.54 | Dividend yield | N/A |
| 200-day MA | $60.63 | Market Cap | 11.00B |
NTRA Stock Price Chart Interactive Chart >
Natera, Inc. (NTRA) Company Bio
Natera Inc. is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The company was founded in 2003 and is based in San Carlos, California.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR TestAUSTIN, Texas, December 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. ("NeoGenomics"). |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
While Natera (NASDAQ:NTRA) shareholders have made 323% in 5 years, increasing losses might now be front of mind as stock sheds 4.7% this weekLong term investing can be life changing when you buy and hold the truly great businesses. And highest quality... |
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNAAUSTIN, Texas, December 21, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. The full study can be found here. |
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera PatentsAUSTIN, Texas, December 11, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx. |
NTRA Price Returns
| 1-mo | 1.78% |
| 3-mo | 34.98% |
| 6-mo | 119.91% |
| 1-year | 78.65% |
| 3-year | -14.81% |
| 5-year | 391.42% |
| YTD | 45.45% |
| 2023 | 55.94% |
| 2022 | -56.99% |
| 2021 | -6.16% |
| 2020 | 195.40% |
| 2019 | 141.33% |
Continue Researching NTRA
Here are a few links from around the web to help you further your research on Natera Inc's stock as an investment opportunity:Natera Inc (NTRA) Stock Price | Nasdaq
Natera Inc (NTRA) Stock Quote, History and News - Yahoo Finance
Natera Inc (NTRA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...